Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153.
Cancer Chemother Pharmacol
; 81(4): 679-686, 2018 04.
Article
in En
| MEDLINE
| ID: mdl-29442139
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Non-Small-Cell Lung
/
Antineoplastic Agents, Immunological
/
Nivolumab
/
Lung Neoplasms
/
Neoplasm Recurrence, Local
Type of study:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Cancer Chemother Pharmacol
Year:
2018
Document type:
Article
Affiliation country:
United States
Country of publication:
Germany